Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VKTX Viking Therapeutics, Inc.

盘前交易 11-03 08:04:20 EST

26.83

-0.45

-1.65%

盘前26.88

+0.05+0.19%

07:56 EST

最高27.90	最低26.54	成交量443.39万
今开27.25	昨收27.28	日振幅4.99%
总市值34.34亿	流通市值33.27亿	总股本1.28亿
成交额1.20亿	换手率3.58%	流通股本1.24亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VKTX","market":"US","secType":"STK","nameCN":"Viking Therapeutics, Inc.","latestPrice":26.83,"timestamp":1793653200000,"preClose":27.28,"halted":0,"volume":4433885,"hourTrading":{"tag":"盘前","latestPrice":26.88,"preClose":26.83,"latestTime":"07:56 EST","volume":8902,"amount":238649.373824,"timestamp":1793710618708,"change":0.05,"changeRate":0.001864,"amplitude":0.025248},"delay":0,"changeRate":-0.01649560117302063,"floatShares":124000000,"shares":128000000,"eps":-5.42,"marketStatus":"盘前交易","change":-0.45,"latestTime":"11-03 08:04:20 EST","open":27.25,"high":27.9,"low":26.54,"amount":119780383.48144999,"amplitude":0.049853,"askPrice":26.85,"askSize":10,"bidPrice":26.76,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-5.42,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793716200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1430280000000,"exchange":"NASDAQ","adjPreClose":26.83,"preHourTrading":{"tag":"盘前","latestPrice":26.88,"preClose":26.83,"latestTime":"07:56 EST","volume":8902,"amount":238649.373824,"timestamp":1793710618708,"change":0.05,"changeRate":0.001864,"amplitude":0.025248},"postHourTrading":{"tag":"盘后","latestPrice":26.92,"preClose":26.83,"latestTime":"19:59 EST","volume":46680,"amount":1252939.2532,"timestamp":1793667548083,"change":0.09,"changeRate":0.003354,"amplitude":0.027208},"volumeRatio":0.9635444011687273,"impliedVol":0.1535,"impliedVolPercentile":0.004},"requestUrl":"/m/hq/s/VKTX","defaultTab":"news","newsList":[{"id":"1180609419","title":"异动解读｜Viking Therapeutics盘中上涨8.08%，Q3每股亏损高于预期后股价反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1180609419","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180609419?lang=zh_cn&edition=full","pubTime":"2026-10-29 22:10","pubTimestamp":1793283043,"startTime":"0","endTime":"0","summary":"10月29日，Viking Therapeutics盘中上涨8.08%，报27.395美元/股，成交额5506.67万美元。消息面上，公司最新披露第三季度每股亏损为1.55美元，高于市场预期的亏损1.06至1.07美元。尽管本次业绩数据弱于预期，但公司近期仍在推进核心肥胖症管线VK2735，10月中旬已启动口服制剂三期项目，且此前获机构给予买入评级及94美元目标价，显示市场仍关注其后续临床进展。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Viking Therapeutics异动上涨，口服减肥药管线受关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193375887","title":"异动解读｜Viking Therapeutics盘中下跌8.01%，瑞银启动覆盖并给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1193375887","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193375887?lang=zh_cn&edition=full","pubTime":"2026-10-17 02:28","pubTimestamp":1792175333,"startTime":"0","endTime":"0","summary":"10月17日，Viking Therapeutics盘中下跌8.01%，报25.1786美元/股，成交额1.24亿美元。近期可见的消息面上，瑞银于10月15日启动覆盖该股，给予买入评级及94美元目标价；市场统计显示，该股分析师一致评级为买入，平均目标价为95.47美元。更早之前，公司于10月14日启动口服VK2735治疗肥胖成人的三期项目，包含肥胖且不伴2型糖尿病、以及肥胖合并2型糖尿病两项研究，主要终点均为68周后体重较基线的百分比变化。尽管近期评级与临床推进偏积极，但当日股价仍出现回落。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Viking盘中下跌，瑞银却给出买入评级","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673309053","title":"Bitget 已上线 USDE、VKTX 等 4 只股票永续合约","url":"https://stock-news.laohu8.com/highlight/detail?id=2673309053","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673309053?lang=zh_cn&edition=full","pubTime":"2026-10-07 19:38","pubTimestamp":1791373091,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据官方公告，Bitget 已上线 USDESTOCK（StablecoinX）、VKTX（Viking Therapeutics）、PCVX（Vaxcyte）及 XP（XP）4 只股票永续合约。\n\n上述合约以 USDT 结算，支持最高 20 倍杠杆及 7×24 小时交易。截至目前，Bitget 平台共支持 337 只股票标的。 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2294669","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","BK4588","VKTX","USDE","BK4585","BK4139","BK4116","BK4599","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102316835","title":"异动解读｜Viking Therapeutics盘中下跌14.12%，4亿美元股票及可转债双重融资计划加剧稀释担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1102316835","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102316835?lang=zh_cn&edition=full","pubTime":"2026-09-24 21:32","pubTimestamp":1790256752,"startTime":"0","endTime":"0","summary":"9月24日，Viking Therapeutics盘中下跌14.12%，报36.01美元/股，成交额1.5亿美元。此前，公司公布GLP-1/GIP双激动剂VK2735维持期研究积极数据，隔周给药方案下患者维持高达97%的减重效果，9月22日单日大涨逾34%。在股价连续大幅上涨后，双重发行带来的股权稀释压力叠加获利回吐情绪，共同推动股价显著回落。Viking Therapeutics是一家临床阶段生物制药公司，专注于开发代谢和内分泌疾病领域的创新疗法，VK2735为其主要肥胖症候选药物，正开发注射剂和口服剂两种剂型。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Viking Therapeutics大跌，双重融资引发稀释担忧","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126359053","title":"异动解读｜Viking Therapeutics盘前下跌8.8%，宣布4亿美元股票及可转债双重融资计划引发稀释担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1126359053","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126359053?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:00","pubTimestamp":1790236838,"startTime":"0","endTime":"0","summary":"9月24日，Viking Therapeutics盘前下跌8.8%，报38.0美元/股，成交额1.54万美元。融资净收益将用于VK2735及VK3019项目的临床开发与商业化推进。此前，公司公布GLP-1/GIP双激动剂VK2735维持期研究积极数据，隔周给药方案下患者维持高达97%的减重效果，9月22日单日大涨逾34%，9月24日盘中延续上行再涨约5%。Viking Therapeutics是一家临床阶段生物制药公司，专注于开发代谢和内分泌疾病领域的创新疗法，VK2735为其主要肥胖症候选药物，正开发注射剂和口服剂两种剂型。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Viking Therapeutics盘前下跌，双重融资引发稀释担忧","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123420599","title":"异动解读｜Viking Therapeutics夜盘下跌8.52%，宣布4亿美元股票及可转债双重融资计划引发稀释担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1123420599","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123420599?lang=zh_cn&edition=full","pubTime":"2026-09-24 08:04","pubTimestamp":1790208288,"startTime":"0","endTime":"0","summary":"9月24日，Viking Therapeutics夜盘下跌8.52%，报38.1美元/股，成交额1143.0美元。融资所得将用于VK2735及VK3019项目的临床开发与商业化推进。这一融资消息在股价连续两日因减肥药VK2735维持期研究积极数据累计大涨后发布，双重发行带来的股权稀释压力叠加获利回吐情绪，共同推动股价盘后显著回落。Viking Therapeutics是一家临床阶段生物制药公司，专注于开发代谢和内分泌疾病领域的创新疗法，VK2735为其主要肥胖症候选药物，正开发注射剂和口服剂两种剂型。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Viking宣布双重融资，股价盘后下挫","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115674055","title":"异动解读｜Viking Therapeutics盘后下跌8.3%，减肥药数据催化后获利回吐压力显现","url":"https://stock-news.laohu8.com/highlight/detail?id=1115674055","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115674055?lang=zh_cn&edition=full","pubTime":"2026-09-24 04:41","pubTimestamp":1790196068,"startTime":"0","endTime":"0","summary":"9月24日，Viking Therapeutics盘后下跌8.3%，报38.1934美元/股，成交额820.8万美元。该数据推动股价在9月22日单日大涨逾34%，盘中报43.07美元期间延续上行。在连续两个交易日累计大幅上涨后，盘后出现明显回落，获利回吐压力显现。Viking Therapeutics是一家临床阶段生物制药公司，专注于开发代谢和内分泌疾病领域的创新疗法，VK2735为其主要肥胖症候选药物，正开发注射剂和口服剂两种剂型。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Viking减肥药数据利好，盘后回落显获利压力","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118146459","title":"异动解读｜Viking Therapeutics盘中上涨5.31%，减肥药VK2735维持期数据催化延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1118146459","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118146459?lang=zh_cn&edition=full","pubTime":"2026-09-24 03:42","pubTimestamp":1790192559,"startTime":"0","endTime":"0","summary":"9月24日，Viking Therapeutics盘中上涨5.31%，报43.0699美元/股，成交额5.11亿美元。消息面上，公司近日公布其GLP-1/GIP双激动剂VK2735维持期研究积极顶线数据，市场热度延续。该结果进一步验证了VK2735在快速扩张的减肥药市场中的竞争潜力，股价在此前公布数据当日曾大涨逾30%，当前延续上行动能。Viking Therapeutics是一家临床阶段生物制药公司，专注于开发代谢和内分泌疾病领域的创新疗法。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Viking Therapeutics异动上涨，减肥药数据催化延续","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187969585","title":"雷达之下：Viking Therapeutics股价因减肥研究消息大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1187969585","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187969585?lang=zh_cn&edition=full","pubTime":"2026-09-22 22:33","pubTimestamp":1790087604,"startTime":"0","endTime":"0","summary":"周二早盘，Viking Therapeutics（VKTX）股价飙升约30%，此前该公司公布了一项令人振奋的试验结果——其实验性减肥注射剂在降低给药频率的情况下，仍能帮助患者有效维持体重下降效果。这一涨幅若得以维持，将创下该股自2024年2月以来的最大单日百分比涨幅。\n在这项研究中，从每周给药转为隔周一次的患者，平均维持了最初减重量的90%。而那些转向每月一次维持剂量的患者，平均保留了85%的减重效果——作为对比，安慰剂组仅为约61%。\n\"疗效数据确实亮眼，但真正让这次发现与众不同的，是采用更少注射次数却依然能保住减重成果这一点，\"花旗分析师Geoff Meacham如此点评。\n","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","OZEM","BK4599","THNR","VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171716591","title":"异动解读｜Viking Therapeutics盘中上涨34.37%，减肥药VK2735维持期研究数据亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1171716591","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171716591?lang=zh_cn&edition=full","pubTime":"2026-09-22 22:04","pubTimestamp":1790085874,"startTime":"0","endTime":"0","summary":"9月22日，Viking Therapeutics盘中上涨34.37%，报40.445美元/股，成交额6.95亿美元。消息面上，公司公布其GLP-1/GIP双激动剂VK2735维持期研究积极顶线数据。此外，在每周17.5毫克剂量下，第33周安慰剂调整后体重降幅达22%，药物安全性和耐受性表现良好。该数据进一步验证了VK2735在快速扩张的减肥药市场中的竞争潜力。Viking Therapeutics是一家临床阶段生物制药公司，专注于开发代谢和内分泌疾病领域的创新疗法。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Viking减肥药数据亮眼，股价大涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142648","title":"Viking Therapeutics涨超35%！减肥药传来捷报：给药频率减半仍维持97%减重","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142648","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669142648?lang=zh_cn&edition=full","pubTime":"2026-09-22 21:50","pubTimestamp":1790085009,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Viking Therapeutics周二盘前一度飙升近50%，此前这家生物科技公司宣布，其实验性肥胖症药物VK2735帮助患者在用药频率从每周一次降至每两周一次的情况下，仍维持了大部分减重成果。这一结果有望进一步增强VK2735在快速扩张的减肥药市场中的竞争地位。截至发稿，VKTX股价上涨近23%。今年以来，该股累计下跌约15%。据了解，VK2735是Viking的主要肥胖症候选药物，正在开发注射剂和口服剂两种剂型。","market":"fut","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499522.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IYH","THNR","BK4588","XLVI","NBDS","PJP","CURE","MEDI","BK4007","FXH","OZEM","TRUH","BK4599","BK4539","NVOX","NVOH","VKTX","PINK","LENZ","RSPH","BK4585","BK4139","FHLC","NVOC"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1114832589","title":"Viking Therapeutics：VK2735 每周17.5毫克剂量下，第33周安慰剂调整后体重降幅达22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114832589","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114832589?lang=zh_cn&edition=full","pubTime":"2026-09-22 19:06","pubTimestamp":1790075174,"startTime":"0","endTime":"0","summary":"Viking Therapeutics公司近日披露，其试验性药物VK2735在每周17.5毫克的给药方案下，于第33周实现了相较于安慰剂高达22%的体重降幅。Viking Therapeutics作为一家专注于代谢疾病疗法开发的生物制药企业，其此番公布的临床数据无疑为整个减重药物赛道注入了一剂强心针。此次公布的数据无疑为Viking Therapeutics的研发管线增添了重要价值，市场对其未来发展前景也抱以更为乐观的预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","OZEM","BK4139","BK4585","THNR","VKTX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165218127","title":"Viking Therapeutics：隔周给药三月后仍维持高达97%的减重效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1165218127","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165218127?lang=zh_cn&edition=full","pubTime":"2026-09-22 19:06","pubTimestamp":1790075173,"startTime":"0","endTime":"0","summary":"Viking Therapeutics传来重磅消息——其试验性疗法在隔周一次的给药方案下，竟能让减重效果持续长达三个月，且幅度最高可达97%。这一数据无疑为肥胖症治疗领域投下了一枚震撼弹。而Viking此次公布的结果，似乎正在打破这一桎梏。市场对此消息反应热烈，Viking的股价在盘前交易中一度大幅攀升，投资者显然对这一里程碑式的数据投下了信任票。但无论如何，Viking已经用这份答卷，向全球代谢疾病领域宣告：减重的持久战，或许正迎来新的拐点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","THNR","BK4585","BK4588","BK4599","VKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190244122","title":"Viking Therapeutics公布GLP-1/GIP激动剂VK2735维持研究积极顶线结果 多种维持给药方案展现前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1190244122","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190244122?lang=zh_cn&edition=full","pubTime":"2026-09-22 19:06","pubTimestamp":1790075171,"startTime":"0","endTime":"0","summary":"Viking Therapeutics今日宣布，其GLP-1/GIP双激动剂VK2735维持期研究取得积极顶线数据。这一结果令人振奋，不仅验证了药物的持续疗效，更凸显了多种维持给药方案的临床潜力。Viking Therapeutics管理层对该结果给予高度评价，认为这一里程碑式的进展将进一步巩固VK2735在代谢疾病治疗领域的竞争地位。业内分析人士指出，VK2735的这一积极成果不仅验证了其作为同类最优候选药物的潜力，也为公司在快速增长的减重与代谢疾病市场中抢占先机奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","VKTX","BK4585","BK4588","BK4139","THNR","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131883109","title":"异动解读｜Viking Therapeutics盘中上涨8.68%，新型减肥药VK3019启动一期临床试验提振市场情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1131883109","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131883109?lang=zh_cn&edition=full","pubTime":"2026-07-08 03:35","pubTimestamp":1783452928,"startTime":"0","endTime":"0","summary":"7月8日，Viking Therapeutics盘中上涨8.68%，报42.07美元/股，成交额1.33亿美元。消息面上，公司近期宣布已启动在研减肥药VK3019的一期单剂量递增临床试验，此前该药已获得美国FDA的新药临床试验申请批准。VK3019为双重淀粉样蛋白和降钙素受体激动剂，该试验为随机、双盲、安慰剂对照研究，旨在评估BMI≥30健康成人中皮下注射VK3019的安全性、耐受性及疗效。多条管线持续推进叠加分析师平均目标价约94.62美元，支撑市场对公司减肥药布局的乐观预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164828121","title":"Viking Therapeutics启动VK3019一期临床试验，评估新型淀粉样蛋白受体激动剂在健康成人中的效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1164828121","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164828121?lang=zh_cn&edition=full","pubTime":"2026-06-24 19:06","pubTimestamp":1782299197,"startTime":"0","endTime":"0","summary":"Viking Therapeutics宣布，已启动一项一期临床研究，旨在评估其新型淀粉样蛋白受体激动剂VK3019在健康成年受试者中的表现。该研究标志着VK3019这一在研药物正式进入人体试验阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","BK4599","VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125765038","title":"Viking Therapeutics在2026年欧洲肥胖症大会上公布VK2735口服给药二期VENTURE试验13周数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1125765038","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125765038?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:06","pubTimestamp":1778583978,"startTime":"0","endTime":"0","summary":"Viking Therapeutics公司在2026年欧洲肥胖症大会上，公布了其候选药物VK2735口服给药二期VENTURE试验为期13周的研究数据。\n该试验旨在评估VK2735在肥胖或超重成人中的疗效与安全性。公布的数据涵盖了药物对患者体重、腰围及其他相关代谢指标的影响。\n研究结果显示，经过13周的治疗，接受VK2735治疗的患者在体重减轻方面取得了具有统计学意义的改善。此外，药物在试验中展现出了可接受的安全性特征。\n这些积极数据进一步支持了VK2735作为一种潜在的口服肥胖治疗方案的持续开发。公司计划基于这些结果，推进该药物的后续临床研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4599","VKTX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517619311","title":"Viking Therapeutics, Inc.盘中异动 早盘大幅上涨5.01%报29.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517619311","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517619311?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:09","pubTimestamp":1741273775,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时09分，Viking Therapeutics, Inc.股票出现波动，股价大幅上涨5.01%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.44%。其相关个股中，Aeon Biopharma, Inc.、Plus Therapeutics, Inc.、Tonix Pharmaceuticals Holding Corp.涨幅较大，Plus Therapeutics, Inc.、Aeon Biopharma, Inc.、Aditxt, Inc.较为活跃，换手率分别为1475.89%、720.61%、73.18%，振幅较大的相关个股有Moolec Science Sa C/Wts 、Aeon Biopharma, Inc.、Coeptis Therapeutics Holdings Inc C/Wts 28/10/2027 ，振幅分别为44.44%、42.11%、39.20%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306230935989ebc93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306230935989ebc93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VKTX","BK4585","BK4139","BK4588","LENZ","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516263769","title":"Viking Therapeutics, Inc.盘中异动 早盘大幅下跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516263769","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516263769?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:52","pubTimestamp":1741013569,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时52分，Viking Therapeutics, Inc.股票出现异动，股价急速下挫5.02%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.06%。其相关个股中，Bioxcel Therapeutics, Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、木薯科学涨幅较大，Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为687.62%、115.08%、86.65%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Entero Therapeutics Inc.、Pliant Therapeutics, Inc.，振幅分别为163.15%、70.53%、40.78%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225249989a15a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225249989a15a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","VKTX","BK4585","BK4588","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514038900","title":"Viking Therapeutics, Inc.盘中异动 股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514038900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514038900?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:23","pubTimestamp":1740669804,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时23分，Viking Therapeutics, Inc.股票出现异动，股价大幅上涨5.03%。Viking Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.14%。其相关个股中，Quoin Pharmaceuticals Ltd、Alpha Tau Medical Ltd C/Wts 、Editas Medicine, Inc.涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为884.66%、177.60%、104.83%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pds Biotechnology Corporation、Quoin Pharmaceuticals Ltd，振幅分别为74.16%、43.51%、34.80%。Viking Therapeutics, Inc.公司简介：Viking Therapeutics Inc 是一家医疗保健服务提供商。VK2809 和 VK0214 是甲状腺激素受体 β 的口服、组织和受体亚型选择性激动剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232324abdf7c41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227232324abdf7c41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","VKTX","BK4139","BK4585","BK4599","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vikingtherapeutics.com","stockEarnings":[{"period":"1week","weight":0.1082},{"period":"1month","weight":-0.1039},{"period":"3month","weight":-0.1855},{"period":"6month","weight":-0.1688},{"period":"1year","weight":-0.2954},{"period":"ytd","weight":-0.2374}],"compareEarnings":[{"period":"1week","weight":-0.0173},{"period":"1month","weight":-0.0228},{"period":"3month","weight":-0.0249},{"period":"6month","weight":0.0249},{"period":"1year","weight":0.1027},{"period":"ytd","weight":0.1029}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viking Therapeutics, Inc.于2012年9月24号在特拉华州成立。该公司是一个临床阶段的生物制药公司，致力于开发新的，第一类或最好的新陈代谢和内分泌失调类疗法。该公司拥有全球独家权利基于许可的配体小分子组合在五个候选药物在临床试验或临床前研究。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.006749},{"month":2,"riseRate":0.545455,"avgChangeRate":0.220725},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.034739},{"month":4,"riseRate":0.454545,"avgChangeRate":0.013541},{"month":5,"riseRate":0.333333,"avgChangeRate":0.076833},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.004304},{"month":7,"riseRate":0.5,"avgChangeRate":-0.000671},{"month":8,"riseRate":0.5,"avgChangeRate":0.013958},{"month":9,"riseRate":0.25,"avgChangeRate":0.049002},{"month":10,"riseRate":0.333333,"avgChangeRate":0.034389},{"month":11,"riseRate":0.416667,"avgChangeRate":-0.018046},{"month":12,"riseRate":0.545455,"avgChangeRate":0.143438}],"exchange":"NASDAQ","name":"Viking Therapeutics, Inc.","nameEN":"Viking Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viking Therapeutics, Inc.,VKTX,Viking Therapeutics, Inc.股票,Viking Therapeutics, Inc.股票老虎,Viking Therapeutics, Inc.股票老虎国际,Viking Therapeutics, Inc.行情,Viking Therapeutics, Inc.股票行情,Viking Therapeutics, Inc.股价,Viking Therapeutics, Inc.股市,Viking Therapeutics, Inc.股票价格,Viking Therapeutics, Inc.股票交易,Viking Therapeutics, Inc.股票购买,Viking Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viking Therapeutics, Inc.(VKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viking Therapeutics, Inc.(VKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}